Pharmacogenomics and Personalized Medicine -a global reality check
Pharmacogenomics, regarded as one of the tangible outcomes of the Human Genome Project, has led to the emergence of Personalized Medicine (1) . In this Special Issue of the Journal, selected manuscripts are based on presentations made at the 3rd Biologie Prospective, Santorini, September/October 2006. During the conference, there was an open forum/round table discussion of the global status of pharmacogenomics. The discussion summary is also included in this issue. A global viewpoint and a snapshot of pharmacogenomics are presented, reflecting the status of and concern about this specialty in facilitating Personalized Medicine. The discussion summary focused on major areas of activities, opportunities, problems and challenges. The consensus on pharmacogenomics was different, as pointed out by Prof. Siest Gerard, Chair of the Santorini meeting series, from that for the 2nd Santorini conference in October, 2004. At that time, there was concern about the direction and possible applications of pharmacogenomics as a nearfuture possibility. One of the outcomes was the publication of a position paper on Pharmacogenomics education. In 2006/2007, it is indeed gratifying to witness that some of recommendations have been implemented both in the US and in Europe, with the realization of clinical pharmacogenomics for patient care. At the same time, awareness of Personalized Medicine (Individualized Medicine or Individualized Therapy) is gaining acceptance. Furthermore, the pivotal role of pharmacogenomics may be regarded as part of the launch pad for the emerging Personalized Medicine. The following points highlight this positive direction.
With the emerging practice of Personalized Medicine, the supporting role of pharmacogenomic/ genomic biomarkers has been advocated since the late 1990s. As pharmacogenomic and, more recently, proteomic biomarkers are increasingly used in classifying patients for drug discovery and development, professional organizations and governmental regulatory agencies in the US, Europe and Japan have been proactively promoting the adoption of these biomarkers. For example, the Personalized Medicine Coalition, headquartered in Washington, DC, has a global membership from major academic centers, professional organizations, and clinical/molecular diagnostic and bioinformatics companies, among others. During its annual meeting, leaders in genomics and key figures in governmental agencies assess the future direction of Personalized Medicine. At the same time, major academic centers (e.g., Ohio State University in Columbus, OH, USA) around the world are establishing Personalized Medicine centers/institutes to assess and to facilitate this trend. Implicit in this process is recognition of the important contributions of genomics/pharmacogenomics, proteomics, metabolomics and other biomarkers, molecular imaging and bioinformatics. In order to advance, these centers/institutes rely on multi-disciplinary approaches.
Just as important, existing and emerging opportunities have created a different landscape for healthcare delivery and for diagnostic companies serving Laboratory Medicine/Pathology. Recently, two imaging companies acquired major clinical and diagnostic companies (Siemens/Bayer completed and GE/Abbott Diagnostics pending). Such a trend lends support to the emerging practice of Personalized Medicine, including molecular imaging. Indeed, the Human Genome Project and the Human Proteome Organization (HUPO) have expanded the horizon of diagnostics, which is converging with other testing approaches such as molecular imaging to offer better personalized testing, and therefore Personalized Medicine.
At the crossroads of these momentous events, it is indeed timely to recognize the core messages distilled from the 2006 Santorini conference. Pharmacogenomics is increasingly used in drug discovery and for approved drugs, as in the case of warfarin therapy, possibly enhanced by CYP2C9 (2) and VKORC1 (3) genotyping. Another example is highlighted by a recent article on the possible application of five genomic biomarkers for non-small-cell lung cancer treated with cisplatin (4), and the accompanying editorial in the New England Journal of Medicine, suggesting approaches such as Personalized Therapy (5) or Personalized Medicine. However, pharmacogenomics should be regarded as a complementary testan adjunct to other existing and emerging diagnostics. Another measure of the reality is the clinical pharmacogenomics survey provided by professional organizations such as the College of American Pathologists this year. Thus, it is indeed timely for the Laboratory Medicine community as a whole to respond to this opportunity by adequately preparing the laboratory and personnel for pharmacognomics testing and development, to share information with and educate clinical colleagues about pharmacogenomics, and to ensure adequate reimbursement. Thus, available and rapidly emerging clinical and scientific evidence and studies, as well as market activities, support the elevation of the practice of Laboratory Medicine to another level. Indeed, it is a great time to be part of the scientific and clinical communities in advancing the art and science of Medicine. It is appro-priate to state that pharmacogenomics add to the global reality of Personalized Medicine.
